Про SPI-Bio

Про компанію

They are founded in 2012 by three entrepreneurial scientists, hoping to devise a full-proof platform for the discovery of clinically-relevant antibodies. Over the years, they have been supported by many prestigious entrepreneurship and scientific awards to create our Nebula Antibody platform and have substantiated this platform through several collaborations with various North American and European pharmaceutical partners. We have also produced over 350 commercial antibodies and submitted several patents for our technologies. In 2015, they took the bold step of initiating their own antibody pipeline, with a primary focus on cancer and gastrointestinal health. Thus far we have advanced 4 candidates to late stages of discovery.